Polomar Health Services, Inc. (PMHS): Cash & Equivalents
$132.2K
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $132.2K | n/m | 2026-05-06, Balance as of period end |
| 2024-12-31 | $6.2K | n/m | 2025-05-22, Balance as of period end |
| 2023-12-31 | $224 | n/a | 2024-04-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $132.2K | n/m |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $28.41M | -4.8% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $1.11M | -27.9% |
| PMGC Holdings Inc. (ELAB) | 2024-12-31 | $3.98M | +19.8% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $11.28M | -90.7% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $2.18M | -33.7% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $40.99M | -41.3% |
| Rallybio Corp (RLYB) | 2025-12-31 | $31.37M | +125.7% |
Compare PMHS, BTAIQ, VCNX, ELAB side by side · Screen every company in Pharmaceutical Preparations ↗